United Therapeutics Corporation
1110 Spring Street
Silver Spring
Maryland
20910
United States
Tel: 301-608-9292
Fax: 301-608-9291
Website: http://www.unither.com/
322 articles with United Therapeutics Corporation
-
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
6/7/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.
-
United claims Liquidia and a former employee misappropriated its trade secrets such as regulatory submissions and detailed financial forecasts for its inhaled treprostinil.
-
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
6/3/2021
First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension
-
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
5/25/2021
United Therapeutics Corporation announced that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.
-
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
4/26/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2021 financial results before the market opens on Wednesday, May 5, 2021 . United Therapeutics will host a teleconference on Wednesday, May 5, 2021 , at 9:00 a.m. Eastern Time .
-
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
4/19/2021
NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications
-
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
4/19/2021
Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA
-
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
4/1/2021
First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need
-
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.
-
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
3/24/2021
United Therapeutics Corporation announced that Dr. Gil Golden, Executive Vice President and Chief Medical Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 10th Annual J.P. Morgan Napa Valley Forum.
-
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference
3/9/2021
United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Oppenheimer 31st Annual Healthcare Conference.
-
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
2/24/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz , President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 41st annual Cowen Health Care Conference
-
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
2/24/2021
United Therapeutics Corporation announced its financial results for the fourth quarter and year ended December 31, 2020.
-
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin®
2/10/2021
United Therapeutics Corporation announced that it has launched commercial sales of the innovative Remunity® Pump for Remodulin® for patients with pulmonary arterial hypertension.
-
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
1/28/2021
A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution
-
Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics
1/14/2021
The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) education and advocacy organization, has announced United Therapeutics' sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with PF nationwide.
-
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
1/13/2021
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T.
-
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.
-
United Therapeutics Announces Agreement To Acquire Priority Review Voucher
12/28/2020
United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.